ProMetic presents preclinical data for prostate and pancreatic cancer at the AA...( Three Developmental Com...)

Three Developmental Compounds Show Early Promise

MONTREAL, April 17 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announced results of three compounds in preclinical studies for prostate and pancreatic cancer at the American Association for Cancer Research ("AACR") Annual Meeting 2008 being held in San Diego this week.

Data on PBI-1737, PBI-0110 and PBI-1308 were presented in poster sessions as follows:

Dr. Mouna Lagroui, ProMetic's Research Scientist, presented data on PBI-1737 in prostate cancer. Results demonstrated that PBI-1737 displayed significant antitumor activity in human prostate cancer both in vitro and in vivo. The in vivo study demonstrated a significant reduction in tumor volume both alone (p < 0.05) and in combination with cyclophosphamide (p < 0.01).

Dr. Lyne Gagnon, ProMetic's Director of Research and Development, Biology, presented preclinical data on the PBI-0110 alone and in combination with gemcitabine in intradermal and orthotopic pancreatic cancer. The study showed that PBI-0110 alone significantly inhibited pancreatic tumor growth in mouse models by as much as 58 percent (p < 0.05) after 44 days. The study also demonstrated a dose dependent inhibition of tumor growth, with the 400mg/kg dose being the most effective, inhibiting growth by nearly 40 percent after 25 days (p < 0.05). Combination therapy of 100mg/kg PBI-0110 and gemcitabine demonstrated similar efficacy. Finally, the study demonstrated increased survival in mice that received the combination therapy of PBI-0110 200mg/kg and gemcitabine.

Finally, Dr. Brigitte Grouix, ProMetic research scientist, presented data on PBI-1308, which demonstrated a reduction of inflammation and cancer cell proliferation through inhibition of NF-kappaB in prostate cancer and inhibition of TNF-alpha, and inflammatory cytokine.

"We continue to be very proud of the progress our compounds are making in early-stage cance
'/>"/>